KDNY - Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

• Chinook Therapeutics ( NASDAQ: KDNY ) on Tuesday said it had got European orphan drug designation for its BION-1301 treatment for primary IgA nephropathy, a type of kidney disease.
• The European drug regulator's orphan designation is given to medicines developed for rare, life-threatening diseases.
• The orphan drug designation for BION-1301 follows a positive opinion from a European drug regulator committee.
• KDNY will be evaluating BION-1301 in a phase 3 study in 2023.
• KDNY stock closed largely unchanged at $17.51 on Friday.

For further details see: